Prasugrel
Prasugrel structure
|
Common Name | Prasugrel | ||
|---|---|---|---|---|
| CAS Number | 150322-43-3 | Molecular Weight | 373.44100 | |
| Density | 1.347 | Boiling Point | 493.5ºC at 760 mmHg | |
| Molecular Formula | C20H20FNO3S | Melting Point | 122 °C | |
| MSDS | Chinese USA | Flash Point | 252.3ºC | |
|
Human valacyclovir hydrolase/biphenyl hydrolase-like protein is a highly efficient homocysteine thiolactonase.
PLoS ONE 9(10) , e110054, (2014) Homocysteinylation of lysine residues by homocysteine thiolactone (HCTL), a reactive homocysteine metabolite, results in protein aggregation and malfunction, and is a well-known risk factor for cardiovascular, autoimmune and neurological diseases. Human plasm... |
|
|
Effect of grapefruit juice on the bioactivation of prasugrel.
Br. J. Clin. Pharmacol. 80 , 139-45, (2015) The P2Y12 inhibitor prasugrel is a prodrug, which is activated after its initial hydrolysis partly by cytochrome P450 (CYP) 3A4. Grapefruit juice, a strong inactivator of intestinal CYP3A4, greatly reduces the activation and antiplatelet effects of clopidogre... |
|
|
Safety of short-term dual antiplatelet therapy after drug-eluting stents: An updated meta-analysis with direct and adjusted indirect comparison of randomized control trials.
Int. J. Cardiol. 181 , 331-9, (2015) Duration of dual antiplatelet therapy (DAPT) following drug-eluting stents (DES) remains controversial and is a topic of ongoing research.Direct and adjusted indirect comparisons of all the recent randomized control trials (RCTs) were performed to evaluate th... |
|
|
Platelet activation biomarkers in Berkeley sickle cell mice and the response to prasugrel.
Thromb. Res. 134(4) , 889-94, (2014) Vaso-occlusive crisis (VOC) is a common complication that occurs in sickle cell disease (SCD) patients. Although underlying mechanisms of VOC remain unclear, platelet activation has been associated with VOC. In the present study, plasma adenine nucleotide mea... |
|
|
Effect of prasugrel in patients with asthma: results of PRINA, a randomized, double-blind, placebo-controlled, cross-over study.
J. Thromb. Haemost. 13(1) , 136-41, (2015) Although experimental studies have demonstrated that platelets are proinflammatory cells, no randomized studies have tested the anti-inflammatory effect of antiplatelet agents in humans. The platelet P2Y12 receptors mediated bronchial inflammation in a mouse ... |
|
|
Hepatic microsomal thiol methyltransferase is involved in stereoselective methylation of pharmacologically active metabolite of prasugrel.
Drug Metab. Dispos. 42(7) , 1138-45, (2014) Prasugrel, a thienopyridine antiplatelet drug, is converted in animals and humans to the pharmacologically active metabolite R-138727 [(2Z)-{1-[(1RS)-2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4-sulfanylpiperidin-3-ylidene}ethanoic acid], which has two chir... |
|
|
Platelet function and coagulation in patients with STEMI and peri-interventional clopidogrel plus heparin vs. prasugrel plus bivalirudin therapy (BRAVE 4 substudy).
Thromb. Res. 137 , 72-8, (2016) In this prespecified BRAVE 4 substudy we examined the antiplatelet and anticoagulant efficacy of clopidogrel plus heparin vs. prasugrel plus bivalirudin in patients with ST-segment elevation myocardial infarction.26 patients received clopidogrel/heparin, 25 p... |
|
|
Reasons for discontinuation of recommended therapies according to the patients after acute coronary syndromes.
Eur. J. Intern. Med. 26(1) , 56-62, (2015) The prescription of recommended medical therapies is a key factor to improve prognosis after acute coronary syndromes (ACS). However, reasons for cardiovascular therapies discontinuation after hospital discharge are poorly reported in previous studies.We enro... |
|
|
Randomized, Double-Blind, Dose-Finding, Phase II Study of Prasugrel in Japanese Patients Undergoing Elective Percutaneous Coronary Intervention.
J. Atheroscler. Thromb. 22 , 557-69, (2015) Prasugrel is a novel platelet P2Y12 receptor blocker with a faster onset of action and greater platelet inhibition with less response variability than clopidogrel. Our objective was to determine the optimal prasugrel dose in Japanese patients undergoing elect... |
|
|
Tailored antiplatelet therapy to improve prognosis in patients exhibiting clopidogrel low-response prior to percutaneous coronary intervention for stable angina or non-ST elevation acute coronary syndrome.
Platelets 26 , 521-9, (2015) To investigate whether an intensified antiplatelet regimen could improve prognosis in stable or non-ST elevation in acute coronary syndrome (ACS) patients exhibiting high on-treatment platelet reactivity (HTPR) on clopidogrel and treated with percutaneous cor... |